Get the Stockscreener App
0.617
2.83%
0.017
Passage Bio Inc stock is traded at $0.617, with a volume of 256.77K.
It is up +2.83% in the last 24 hours and down -6.52% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
See More
Previous Close:
$0.60
Open:
$0.63
24h Volume:
256.77K
Relative Volume:
0.36
Market Cap:
$38.11M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-0.5274
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+3.35%
1M Performance:
-6.52%
6M Performance:
-31.44%
1Y Performance:
-31.36%
1-Day Range:
$0.5976
$0.63
1-Week Range:
$0.5606
$0.642
52-Week Range:
$0.451
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.617 | 38.11M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics - MSN
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Orbimed advisors reduces stake in Passage Bio for $142,223 By Investing.com - Investing.com South Africa
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MSN
Orbimed advisors reduces stake in Passage Bio for $142,223 - Investing.com
Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel to Monitor Treatment Journey for Patients with Traumatic Brain Injury and Alzheimer's - BioSpace
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway - BioSpace
Geode Capital Management LLC Has $351,000 Position in Nutriband Inc. (NASDAQ:NTRB) - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Geode Capital Management LLC - Defense World
Head-To-Head Comparison: Passage Bio (NASDAQ:PASG) vs. JATT Acquisition (NYSE:JATT) - Defense World
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Passage Bio announces data from upliFT-D study in FTD-GRN, provides update - TipRanks
Passage Bio Restructures and Extends Cash Runway - TipRanks
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates - The Manila Times
Passage Bio's FTD Treatment Shows Promise in Clinical Trial, Plans Lower Dose Strategy - StockTitan
Orbimed advisors sells shares in Passage Bio for $103,305 By Investing.com - Investing.com Canada
Orbimed advisors sells shares in Passage Bio for $103,305 - Investing.com India
Frontotemporal Dementia Clinical and Non-Clinical Studies, - openPR
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 7, 2025 - BioSpace
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage Bio sees $241,038 stock purchase by Lynx1 Capital - Investing.com Australia
Passage Bio (NASDAQ:PASG) & Apogee Therapeutics (NASDAQ:APGE) Head-To-Head Contrast - Defense World
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely? - Yahoo Finance
Orbimed advisors sells $138,192 in Passage Bio shares By Investing.com - Investing.com Nigeria
Orbimed advisors sells $138,192 in Passage Bio shares - Investing.com India
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - BioSpace
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):